Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam tosilate plus sufentanil versus propofol plus sufentanil for painless gastroscopy in cirrhosis
ChiCTR2100042179Phase 4Recruiting
- Sponsor
- Peking University Shenzhen Hospital
- Start
- Feb 2021
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of remimazolam, sufentanil and propofol in Cirrhosis (2 arms), sponsored by Peking University Shenzhen Hospital. Primary endpoints: Physician satisfaction with gastroscopy, Degree of respiratory depression and 10 more. Started Feb 2021; status: recruiting.
02
Drugs
remimazolamsufentanilpropofol
03
Conditions
Cirrhosis
Beyond the preview
Go deeper on ChiCTR2100042179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100042179.